[[abstract]]BACKGROUND: In Taiwan, two rotavirus vaccines are available on the private market, but are not included in the National Immunization Program (NIP). To help assess whether to include rotavirus vaccines in the NIP, we examined the potential impact and cost-effectiveness of vaccination, from the health care system perspective alone. METHODS: We used a Microsoft Excel-based model to assess rotavirus vaccination impact on rotavirus disease burden and the cost-effectiveness of 2-dose and 3-dose vaccination programs among a birth cohort of Taiwanese children followed for 5 years. Principal model inputs included data on rotavirus disease burden and related healthcare costs, vaccination cost and coverage rates, and vaccine efficacy. Prin...
Objectives: To estimate: 1) rotavirus disease burden in New Zealand children aged under 5 years, and...
BACKGROUND: Rotavirus is the leading cause of severe gastroenteritis in children 500,000 deaths annu...
[[abstract]]Background: Two rotavirus vaccines (RV1 and RV5) are available on the private market in ...
[[abstract]]BACKGROUND: In Taiwan, two rotavirus vaccines are available on the private market, but a...
Background Rotavirus is a major cause of diarrhoea in children less than five years old in Thailand....
BACKGROUND: Rotavirus is the leading cause of severe gastroenteritis in children worldwide. We evalu...
Abstract Background Rotavirus infection causes considerable disease burden of acute gastroenteritis ...
[[abstract]]Background: The disease burden and associated medical costs of rotavirus infections in i...
The authors assessed the cost-effectiveness of rotavirus vaccination to develop an evidence-based na...
Background: Cost effectiveness studies are essential to assess the real value of interventions with...
Introduction World Health Organization recommends rotavirus vaccine for all national immunization pr...
Background: This study aims to critically review available cost-effectiveness models for rotavirus v...
BACKGROUND: In developing countries rotavirus is the leading cause of severe diarrhoea and diarrhoea...
OBJECTIVES: To assess the cost-effectiveness of universal rotavirus immunization, explicitly the use...
ABSTRACTObjectivesTo estimate: 1) rotavirus disease burden in New Zealand children aged under 5 year...
Objectives: To estimate: 1) rotavirus disease burden in New Zealand children aged under 5 years, and...
BACKGROUND: Rotavirus is the leading cause of severe gastroenteritis in children 500,000 deaths annu...
[[abstract]]Background: Two rotavirus vaccines (RV1 and RV5) are available on the private market in ...
[[abstract]]BACKGROUND: In Taiwan, two rotavirus vaccines are available on the private market, but a...
Background Rotavirus is a major cause of diarrhoea in children less than five years old in Thailand....
BACKGROUND: Rotavirus is the leading cause of severe gastroenteritis in children worldwide. We evalu...
Abstract Background Rotavirus infection causes considerable disease burden of acute gastroenteritis ...
[[abstract]]Background: The disease burden and associated medical costs of rotavirus infections in i...
The authors assessed the cost-effectiveness of rotavirus vaccination to develop an evidence-based na...
Background: Cost effectiveness studies are essential to assess the real value of interventions with...
Introduction World Health Organization recommends rotavirus vaccine for all national immunization pr...
Background: This study aims to critically review available cost-effectiveness models for rotavirus v...
BACKGROUND: In developing countries rotavirus is the leading cause of severe diarrhoea and diarrhoea...
OBJECTIVES: To assess the cost-effectiveness of universal rotavirus immunization, explicitly the use...
ABSTRACTObjectivesTo estimate: 1) rotavirus disease burden in New Zealand children aged under 5 year...
Objectives: To estimate: 1) rotavirus disease burden in New Zealand children aged under 5 years, and...
BACKGROUND: Rotavirus is the leading cause of severe gastroenteritis in children 500,000 deaths annu...
[[abstract]]Background: Two rotavirus vaccines (RV1 and RV5) are available on the private market in ...